Economic Development, Health Care, and Human Resources

Medical company investing $2.8M in operation

December 15, 2016
Text Size:
NxGen MDx
Grand Rapids-based NxGen MDx is a medical diagnostics lab for genetic screening. Photo via

A molecular diagnostics lab for genetic screening is adding 37 “high-tech” jobs and investing $2.8 million in its local operation.

Grand Rapids-based NxGen MDx is planning an expansion at its West Side location, at 801 Broadway Ave. NW, according to The Right Place yesterday.

The expansion will increase the lab’s testing capacity to meet an expected 300-percent increase in demand over last year.

The company plans to add the jobs and make its investment over the next three years.

NxGen MDx chose to expand in Grand Rapids over a competing site in Florida.


The company received support for its project from the Michigan Strategic Fund in the form of $250,000.

The City of Grand Rapids is considering approval of a local property tax abatement to support the project.

The Right Place in Grand Rapids, an economic development nonprofit, assisted NxGen MDx in securing financial incentives for the project.

“The expert support provided by The Right Place, combined with the collaborative resources of Grand Rapids’ Medical Mile made the decision easy on where the next chapter of our growth would take place,” said Kristin Sherman, CFO, NxGen MDx.

Eric Icard, a senior business development manager at The Right Place, said Grand Rapids’ “life sciences cluster continues to see significant growth, and NxGen is yet the latest example of that growth.”

“Companies like NxGen are not only great for our community in terms of new jobs, but they also raise national awareness of West Michigan within the industry,” he said.

NxGen MDx

Founded in 2014 after graduating from the Grand Rapids SmartZone life science incubator, NxGen MDx offers genetic screens for inherited diseases like cystic fibrosis, spinal muscular atrophy and fragile X syndrome.

NxGen also provides genetic counselors and customer service to help patients better understand the results of their testing.

Recent Articles by Jesse O'Brien

Editor's Picks

Comments powered by Disqus